Phaseline

Companies › Sagimet Biosciences

Sagimet Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Immunology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Denifanstat
DGAT2 inhibitor
DGAT2Phase 3Acne VulgarisAug 2027
TVB-3567–Phase 1AcneJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06989840TVB-3567Phase 1AcneImmunologyJan 2027
NCT07863193DenifanstatPhase 3Acne VulgarisImmunologyAug 2027

From the company's SEC filings

Cash and short-term investments of $258m on 2026-06-30; operating cash outflow about $40m a year; runway about 77 months at that burn, to Dec 2032; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DGAT2 (1)

Companies with the same targets

–

Companies built like this

BioCryst Pharmaceuticals Hangzhou Highlightll Pharmaceutical Veradermics Palisade Bio Prime Gene Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.